Is CJC-1295 Legal in 2026? The FDA Record and the Compounding Reversal, Explained

Short answer: CJC-1295's status in 2026 is more nuanced than most pages suggest. It was formerly on FDA's 503A Category 2 list, was removed when its nominations were withdrawn, and FDA's advisory committee recommended against bulks-list inclusion in December 2024. Here is the record, channel by channel. Not legal advice.

Legality pages rot fast, so this one is dated: the record below is accurate as of August 2026, it is sourced to FDA documents, and it is educational. The broader sourcing framework lives in our safety and sourcing guide.

The nomination arc: Category 2, then withdrawn

CJC-1295 was nominated for the 503A Bulks List — the list of bulk substances eligible for use by compounding pharmacies — by nominators including Wells Pharmacy Network (2015) and LDT Health Solutions (2018). Under the list framework FDA established in 2019, it was placed in Category 2: "Bulk Drug Substances that Raise Significant Safety Risks."

Here's where most of the internet stops reading, and gets it wrong. FDA's current list notes that CJC-1295 was removed from Category 2 because the nominations were withdrawn — and FDA then took the five CJC-1295-related substances up on its own initiative. So a page describing CJC-1295 as currently "Category 2" is working from a stale record. The accurate 2026 framing: formerly Category 2, now evaluated on FDA's own initiative. The record moves; the good pages move with it.

The December 4, 2024 PCAC: recommended against

At the December 4, 2024 Pharmacy Compounding Advisory Committee meeting, FDA proposed that all five CJC-1295-related bulk drug substances — the free base, acetate, and three DAC forms — not be included on the 503A Bulks List. The cited concerns: physicochemical characterization gaps, no historical compounding-use data, nonclinical safety signals, limited clinical safety data, and no effectiveness data for growth-hormone deficiency.

Two disciplines apply when reading that. First, it's an advisory recommendation, not a final rule — the rulemaking horizon runs to roughly mid-to-late 2027. Second, a classification decision is not a harm verdict: "not recommended for the bulks list" is a regulatory-scrutiny statement about the compounding channel, not a finding that the molecule injures people. Our CJC-1295 side effects page holds the same line from the safety side.

The category is moving — even where this molecule isn't (yet)

Zoom out and the 2026 picture is one of momentum. At the July 23–24, 2026 PCAC meeting, the committee recommended six of seven reviewed peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon — for the bulks list, with rulemaking to follow. NMN's supplement eligibility was formally reinstated by FDA in late 2025. The direction of travel across the category is toward regulated, structured access.

CJC-1295 itself was not taken up at the July 2026 meeting — the December 2024 recommendation remains the latest on-record advisory action for it. But the same process that re-examined those six can revisit others; nominations and agency initiatives are how substances enter, leave, and re-enter this record. The timeline and votes are tracked on our FDA panel July 2026 page; the parallel BPC-157 record is in BPC-157 FDA status.

What this means for a consumer buying a strip

Channel by channel, because that's how the law is organized:

• Compounded-drug channel: CJC-1295 is not on the 503A bulks list, FDA has recommended against including it, and final rulemaking is pending (~2027). Compounding status is unresolved.
• Research-chemical channel: "for research use only" sales exist in the market; that label is the seller's legal posture, not a consumer-protection status — the distinction is mapped in research vs brand peptides.
• Supplement-style strip channel: products like the CJC-1295/Ipamorelin strip (250/250 mcg, 20-count, Citrus — product page) are sold as wellness products, not drugs. No wellness product inherits a drug channel's status, and no page — including ours — can hand you a flat "legal to buy" verdict, because that flat answer doesn't exist. Any page offering it is guessing.

What the record shows — and what it doesn't

Documented: the nomination-and-withdrawal arc; the December 4, 2024 recommendation against all five substances; CJC-1295's absence from the July 2026 agenda; the six-of-seven recommendations that did happen there.

In motion: the 2027-horizon rulemaking process; a category-wide re-examination that has already produced the NMN reinstatement and six favorable advisory votes.

Not determined: any final rule; any flat consumer-level legality verdict.

The honest passage

One passage, and it's the same one we'd want as readers: this page can't tell you the molecule has a settled legal status — because it doesn't. The nomination was withdrawn, the advisory committee was told to keep it off the list, and no final rule exists. What we can do is keep the record accurate and dated, which is more than most of this SERP offers. Anyone needing certainty for a decision with legal exposure should ask a lawyer, not a blog — including ours.

The bottom line

The honest headline is better than the lazy one: CJC-1295 is not currently a Category 2 substance, the compounding question is mid-rulemaking rather than closed, and the peptide category around it is moving toward more regulated access, not less. For a consumer, the actionable picture is channel-by-channel clarity — and a dated page that will be re-reviewed by January 31, 2027, or sooner if rulemaking lands. That record-keeping is the actual answer to the query.

---

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

This content is for educational purposes only and is not medical advice. Consult a licensed healthcare provider before starting any new product. Individual results vary.